Antisense Technology

2-5A Drug May Inhibit Respiratory Syncytial Virus in Infants

Published in Gene Therapy Weekly, March 17th, 1997

A drug based on 2-5A antisense technology from Atlantic Pharmaceuticals, Half Moon Bay, California, achieved up to 95 percent eradication rates of respiratory syncytial virus (RSV) in infected tissue culture.

RSV is the principle cause of lower respiratory infections such as pneumonia and brochiolitis in infants and children, and is responsible for at least 90,000 hospitalizations and 4,500 deaths in the United States each year.

The Cleveland Clinic, Ohio, conducted the study in collaboration with the U.S. National Institutes of Health (NIH). Gemini Technologies, Inc. is the exclusive licensee of the 2-5A antisense technology. Results of the study...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-03-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry